In the postgenomic era, computer-aided drug design
(CADD) has considerably extended its range of applications,
spanning almost all stages in the drug discovery
pipeline, from target identification to lead discovery,
from lead optimization to preclinical or clinical trials.
Two new technologies of CADD associated with target
identification and new chemical entity discovery will be
the focus of this review.